Spots Global Cancer Trial Database for Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Official Title: A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients With Cutaneous Squamous Cell Carcinoma (CSCC) or Basal Cell Carcinoma (BCC)
Study ID: NCT03889912
Interventions
Study Description
Brief Summary: This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC). The aim of the study is to evaluate the safety and tolerability (how your body reacts to the drug) of cemiplimab (also known as REGN2810). The first part of the study tested several different doses of cemiplimab given weekly for 12 weeks. The study is also looking at several other research questions, including: * What side effects may happen from taking the study drug * To see effect of cemiplimab on the tumor * How much study drug is in the blood at different times
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Medical Dermatology Specialists, Phoenix, Arizona, United States
Regeneron Research Facility, Redwood City, California, United States
Therapeutics Clinical Research, San Diego, California, United States
Dermatology Associates of the Palm Beaches, Delray Beach, Florida, United States
Regeneron Research Facility, Tampa, Florida, United States
Regeneron Research Facility, Atlanta, Georgia, United States
Regeneron Research Facility, Louisville, Kentucky, United States
Northeast Dermatology Associates, Beverly, Massachusetts, United States
NYU Langone, New York, New York, United States
Rochester Dermatologic Surgery, Victor, New York, United States
Duke Cancer Center, Durham, North Carolina, United States
MD Anderson Cancer Center, Houston, Texas, United States
INOVA Schar Cancer Institute, Fairfax, Virginia, United States
Contact Details
Name: Clinical Trial Management
Affiliation: Regeneron Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
